Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)
Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –
Vertex Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vertex Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $12.59B, up 10.2% year over year. For fiscal 2025 it was $12.00B, up 8.9% from the year before. Over ten years it grew 27.8% a year on average. The highest annual figure on record is $12.00B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.00B | +8.9% |
| FY2024 | Dec 31, 2024 | $11.02B | +11.7% |
| FY2023 | Dec 31, 2023 | $9.87B | +10.5% |
| FY2022 | Dec 31, 2022 | $8.93B | +17.9% |
| FY2021 | Dec 31, 2021 | $7.57B | +22.1% |
| FY2020 | Dec 31, 2020 | $6.21B | +49.1% |
| FY2019 | Dec 31, 2019 | $4.16B | +36.6% |
| FY2018 | Dec 31, 2018 | $3.05B | +22.5% |
| FY2017 | Dec 31, 2017 | $2.49B | +46.2% |
| FY2016 | Dec 31, 2016 | $1.70B | +64.9% |
| FY2015 | Dec 31, 2015 | $1.03B | +77.9% |
| FY2014 | Dec 31, 2014 | $580.42M | -52.1% |
| FY2013 | Dec 31, 2013 | $1.21B | -20.6% |
| FY2012 | Dec 31, 2012 | $1.53B | +8.3% |
| FY2011 | Dec 31, 2011 | $1.41B | +883.9% |
| FY2010 | Dec 31, 2010 | $143.37M | +40.7% |
| FY2009 | Dec 31, 2009 | $101.89M | -41.9% |
| FY2008 | Dec 31, 2008 | $175.50M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.33B | +12.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.99B | +7.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.19B | +9.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.08B | +11.0% |
| Q2 FY2025 | Jun 30, 2025 | $2.96B | +12.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.77B | +3.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.91B | +15.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.77B | +11.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.65B | +6.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.69B | +13.3% |
| Q4 FY2023 | Dec 31, 2023 | $2.52B | +9.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.48B | +6.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.49B | +13.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.37B | +13.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.30B | +11.1% |
| Q3 FY2022 | Sep 30, 2022 | $2.33B | +17.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.20B | +22.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.10B | +21.6% |
| Q4 FY2021 | Dec 31, 2021 | $2.07B | +27.3% |
| Q3 FY2021 | Sep 30, 2021 | $1.98B | +29.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.79B | +17.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.72B | +13.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.63B | +15.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.54B | +62.0% |
| Q2 FY2020 | Jun 30, 2020 | $1.52B | +62.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.52B | +76.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.41B | +62.4% |
| Q3 FY2019 | Sep 30, 2019 | $949.83M | +21.1% |
| Q2 FY2019 | Jun 30, 2019 | $941.29M | +25.1% |
| Q1 FY2019 | Mar 31, 2019 | $858.44M | +34.0% |
| Q4 FY2018 | Dec 31, 2018 | $870.11M | +33.5% |
| Q3 FY2018 | Sep 30, 2018 | $784.54M | +35.7% |
| Q2 FY2018 | Jun 30, 2018 | $752.16M | +38.2% |
| Q1 FY2018 | Mar 31, 2018 | $640.80M | -10.3% |
| Q4 FY2017 | Dec 31, 2017 | $651.63M | +42.1% |
| Q3 FY2017 | Sep 30, 2017 | $578.17M | +39.7% |
| Q2 FY2017 | Jun 30, 2017 | $544.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $714.72M | – |
| Q4 FY2016 | Dec 31, 2016 | $458.71M | – |
| Q3 FY2016 | Sep 30, 2016 | $413.78M | – |
See a number that looks wrong?